PALISADE BIO, INC. (PALI)
Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
Weatherford Awarded Multi-Region Managed Pressure Drilling and Global Aftermarket Agreement with Noble
Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update
InterDigital to Present at Four Upcoming Investor Conferences
Forward Industries and RockawayX Co-Lead Strategic Investment in OnRe to Accelerate Onchain Reinsurance on Solana
Intercontinental Exchange Reports April 2026 Statistics
Extreme Accelerates Leadership Position in Next-Generation Wi-Fi 7
Hertz Car Sales Continues Retail Expansion with Digital Showroom on eBay
Introducing Extreme Agent ONE: A Smarter, Faster, Autonomous Approach to Enterprise Networking
UiPath Automation Suite™ Delivers On-Premises Agentic AI for the Public Sector